Ironwood Pharmaceuticals posts Q1 profit of $40.8 million on $106.5 million revenue, guides 2026 revenue to $450-$475 million
- Q1 2026 net income reported as $41 million, with LINZESS U.S. sales up 97% YoY
- Ironwood Pharmaceuticals affirms its 2026 guidance after releasing Q1 2026 financial results
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.